53% of patients experienced complete remission from depression in Phase 2a study.
Microdoses of LSD led to a 60% reduction in depressive symptoms in patients participating in a MindBio Therapeutics Corp. clinical trial.
MindBio, which lists on the Canadian Securities Exchange, is an Australian company focused on developing psychedelic medicines in sub-hallucinogenic, or microdose, amounts.
The company announced on Feb. 26 the results of its Phase 2a study testing patients with major depressive disorder using its MB22001titratable form of LSD.
The participants took a dose every few days, which produced mildly noticeable effects.
The results demonstrate the safe and effective use of a psychedelic medicine in microdose amounts, the company said.
After eight weeks of dosing, 53% of patients experienced complete remission from depression, according to MindBio.
The company is currently evaluating post-treatment effects for continued remission and will report the findings in medical journals.